Forward Pharma A/S is a biopharmaceutical company which engages in the research and production of a medicinal treatment for multiple sclerosis and psoriasis. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company is engaged in segments of the pharmaceutical and biotechnological industries. Forward Pharma is actively developing FP187, a proprietary formulation of dimethyl fumarate ("DMF"), for the treatment of multiple sclerosis ("MS") patients. The company has conducted a pre-clinical program and has completed several Phase I and Phase II clinical trials for the product FP187.